BullishWhales · Analysts · Analyst Profile
Analyst rating accuracy & track record
Matthew Barcus does not yet have enough resolved 12-month calls to carry a published score. Check back as their ratings mature.
Ratings & price targets
| Stock | Rating | Price target | Rated | 12-mo vs sector | PT hit |
|---|---|---|---|---|---|
 ZURAZura Bio Limited Class A Ordinary Shares | Buy | $10.00 | Mar 2025 | +343.4% | Miss |
| ZURAZura Bio Limited Class A Ordinary Shares | Buy | $12.00 | Nov 2024 | −17.6% | Miss |
 PPBTPurple Biotech | Buy | $11.00 | May 2023 | −86.6% | Miss |
| PPBTPurple Biotech | Buy | $11.00 | Feb 2023 | −66.2% | Miss |
| PPBTPurple Biotech | Buy | $11.00 | Sep 2022 | −48.0% | Miss |
Go to
Browse the full analyst leaderboardHow analyst accuracy is scored
Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.